Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...

At week 140, 80.8% of those administered guselkumab achieved clinical remission.

In patients with ulcerative colitis who had endoscopic healing, achieving transmural healing was associated with longer relapse-free survival. Women and those who had received multiple advanced ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...

Artificial intelligence (AI) is used in ulcerative colitis to assist in the assessment, monitoring, and management of disease. To explain how this technology is being applied in the clinical setting, ...

Floris de Voogd, MD; Elsa A. van Wassenaer, MD; Aart Mookhoek, MD, PhD; Steven Bots, MD; Sara van Gennep, MD; Mark Löwenberg, MD, PhD; Geert R. D’Haens, MD, PhD ...

The diagnosis of ulcerative colitis (UC) is based on clinical evaluation and medical history and confirmed through laboratory, radiologic, endoscopic and histologic findings. Before making the ...

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

Biotechnology company Abivax has enrolled its first patient in a phase 3 trial of Obefazimod, a treatment for severe ulcerative colitis, according to an Oct. 11 press release sent to Becker’s. The ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...